Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs

被引：2

作者：

Butters, Julie ^{[1
]}

Brown, Alex ^{[1
]}

Griffith, Liddy ^{[1
]}

Kim, Susan ^{[1
]}

Nicholls, Stephen J. ^{[1
]}

机构：

[1] Univ Adelaide, South Australian Hlth & Med Res Inst, POB 11060, Adelaide, SA 5001, Australia

来源：

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | 2017年 / 17卷 / 06期

关键词：

ACUTE-CORONARY-SYNDROME; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR-DISEASE; STATIN THERAPY; HIGH-RISK; LDL CHOLESTEROL; HDL CHOLESTEROL; EFFLUX CAPACITY; HEART-DISEASE; DOUBLE-BLIND;

D O I：

10.1007/s40256-017-0231-6

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

While statins have formed the cornerstone of strategies for cardiovascular prevention, the residual risk related to low-density lipoprotein cholesterol (LDL-C) and other lipoprotein factors provides a landscape for development of new therapies. However, a number of lipid-modifying therapies have failed to reduce cardiovascular event rates in contemporary clinical trials of statin-treated patients. The factors considered in outcome measure selection for clinical trials of novel lipid-lowering therapies are reviewed. Evaluation of lipid-modifying drugs in clinical trials spans a spectrum from their effects on conventional circulating lipid parameters through to their impact on atherosclerotic plaque and ultimately clinical outcomes. The design of these trials has an important impact on the result and ultimate interpretation of these studies.

引用

页码：447 / 452

页数：6

共 50 条

[1] 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) [J].

Catapano, Alberico L. ;

Graham, Ian ;

De Backer, Guy ;

Wiklund, Olov ;

Chapman, M. John ;

Drexel, Heinz ;

Hoes, Arno W. ;

Jennings, Catriona S. ;

Landmesser, Ulf ;

Pedersen, Terje R. ;

Reiner, Zeljko ;

Riccardi, Gabriele ;

Taskinen, Marja-Riita ;

Tokgozoglu, Lale ;

Verschuren, W. M. Monique ;

Vlachopoulos, Charalambos ;

Wood, David A. ;

Luis Zamorano, Jose .

ATHEROSCLEROSIS, 2016, 253 :281-344

[2] Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].

Baigent, C. ;

Blackwell, L. ;

Emberson, J. ;

Holland, L. E. ;

Reith, C. ;

Bhala, N. ;

Peto, R. ;

Barnes, E. H. ;

Keech, A. ;

Simes, J. ;

Collins, R. .

LANCET, 2010, 376 (9753) :1670-1681

[3] Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].

Baigent, C ;

Keech, A ;

Kearney, PM ;

Blackwell, L ;

Buck, G ;

Pollicino, C ;

Kirby, A ;

Sourjina, T ;

Peto, R ;

Collins, R ;

Simes, J .

LANCET, 2005, 366 (9493) :1267-1278

[4]

Ballantyne CM, 1998, AM J CARDIOL, V82, p3Q

[5] Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies [J].

Banach, Maciej ;

Serban, Corina ;

Sahebkar, Amirhossein ;

Mikhailidis, Dimitri P. ;

Ursoniu, Sorin ;

Ray, Kausik K. ;

Rysz, Jacek ;

Toth, Peter P. ;

Muntner, Paul ;

Mosteoru, Svetlana ;

Garcia-Garcia, Hector M. ;

Hovingh, G. Kees ;

Kastelein, John J. P. ;

Serruys, Patrick W. .

BMC MEDICINE, 2015, 13

[6] Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel [J].

Banach, Maciej ;

Rizzo, Manfredi ;

Toth, Peter P. ;

Farnier, Michel ;

Davidson, Michael H. ;

Al-Rasadi, Khalid ;

Aronow, Wilbert S. ;

Athyros, Vasilis ;

Djuric, Dragan M. ;

Ezhov, Marat V. ;

Greenfield, Robert S. ;

Hovingh, G. Kees ;

Kostner, Karam ;

Serban, Corina ;

Lighezan, Daniel ;

Fras, Zlatko ;

Moriarty, Patrick M. ;

Muntner, Paul ;

Goudev, Assen ;

Ceska, Richard ;

Nicholls, Stephen J. ;

Broncel, Marlena ;

Nikolic, Dragana ;

Pella, Daniel ;

Puri, Raman ;

Rysz, Jacek ;

Wong, Nathan D. ;

Bajnok, Laszlo ;

Jones, Steven R. ;

Ray, Kausik K. ;

Mikhailidis, Dimitri P. .

ARCHIVES OF MEDICAL SCIENCE, 2015, 11 (01) :1-23

[7] HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events [J].

Barter, Philip ;

Gotto, Antonio M. ;

LaRosa, John C. ;

Maroni, Jaman ;

Szarek, Michael ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Bittner, Vera ;

Fruchart, Jean-Charles .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (13) :1301-1310

[8] Effects of torcetrapib in patients at high risk for coronary events [J].

Barter, Philip J. ;

Caulfield, Mark ;

Eriksson, Mats ;

Grundy, Scott M. ;

Kastelein, John J. P. ;

Komajda, Michel ;

Lopez-Sendon, Jose ;

Mosca, Lori ;

Tardif, Jean-Claude ;

Waters, David D. ;

Shear, Charles L. ;

Revkin, James H. ;

Buhr, Kevin A. ;

Fisher, Marian R. ;

Tall, Alan R. ;

Brewer, Bryan .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2109-2122

[9] Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease [J].

Besler, Christian ;

Heinrich, Kathrin ;

Rohrer, Lucia ;

Doerries, Carola ;

Riwanto, Meliana ;

Shih, Diana M. ;

Chroni, Angeliki ;

Yonekawa, Keiko ;

Stein, Sokrates ;

Schaefer, Nicola ;

Mueller, Maja ;

Akhmedov, Alexander ;

Daniil, Georgios ;

Manes, Costantina ;

Templin, Christian ;

Wyss, Christophe ;

Maier, Willibald ;

Tanner, Felix C. ;

Matter, Christian M. ;

Corti, Roberto ;

Furlong, Clement ;

Lusis, Aldons J. ;

von Eckardstein, Arnold ;

Fogelman, Alan M. ;

Luescher, Thomas F. ;

Landmesser, Ulf .

JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (07) :2693-2708

[10] Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy [J].

Boden, William E. ;

Probstfield, Jeffrey L. ;

Anderson, Todd ;

Chaitman, Bernard R. ;

Desvignes-Nickens, Patrice ;

Koprowicz, Kent ;

McBride, Ruth ;

Teo, Koon ;

Weintraub, William .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (24) :2255-2267

← 1 2 3 4 5 →